B10.81 Human herpesvirus 6 infection

Name of the Condition

• Human herpesvirus 6 infection

Summary

Human herpesvirus 6 (HHV-6) infection is caused by the HHV-6 virus, a member of the Herpesviridae family. The infection can present with diverse clinical manifestations, ranging from mild, self-limiting illnesses to severe, systemic disease. Primary infection often occurs in early childhood and may be asymptomatic or associated with febrile illness. Reactivation can occur in immunocompromised individuals, leading to more serious complications.

Causes

Human herpesvirus 6 infection is caused by the HHV-6 virus, which is transmitted through direct contact with infected bodily fluids, respiratory droplets, or vertical transmission (e.g., from mother to fetus). The virus establishes lifelong latency in host cells after primary infection and may reactivate under conditions of immunosuppression.

Risk Factors

• Immunocompromised states, such as HIV/AIDS, organ transplantation, or chemotherapy.
• Primary infection in young children.
• Reactivation in individuals with weakened immune systems.

Symptoms

• Febrile illness, particularly in infants (e.g., roseola infantum).
• Rash, often after fever subsides.
• Lymphadenopathy.
• In immunocompromised patients, potential for severe complications like encephalitis or pneumonitis.

Diagnosis

Diagnosis of HHV-6 infection is typically based on clinical presentation and laboratory testing. Serological tests to detect HHV-6 antibodies or nucleic acid amplification tests (e.g., PCR) to identify viral DNA in blood or tissue samples may be used. Distinguishing between primary infection and reactivation may require additional testing, such as measuring viral load or antibody titers.

Treatment Options

Treatment for HHV-6 infection is generally supportive, focusing on managing symptoms (e.g., antipyretics for fever). In severe cases, particularly in immunocompromised patients, antiviral medications like ganciclovir or foscarnet may be considered, though their efficacy is not universally established. Management of underlying immunosuppression is also critical.

Prognosis and Follow-Up

The prognosis for HHV-6 infection is generally favorable in immunocompetent individuals, with most cases resolving without long-term sequelae. In immunocompromised patients, outcomes depend on the severity of the infection and the underlying condition. Follow-up may involve monitoring for reactivation or complications, especially in high-risk groups.

Complications

• Encephalitis, particularly in immunocompromised individuals.
• Pneumonitis or respiratory involvement.
• Hepatitis or other organ-specific inflammation.
• Reactivation in transplant recipients, potentially affecting graft function.

Lifestyle & Prevention

• Good hygiene practices, such as handwashing, may reduce transmission risk.
• Avoiding close contact with individuals showing symptoms of active infection.
• For immunocompromised patients, adherence to prophylactic measures and regular monitoring is important.

When to Seek Professional Help

Seek medical attention if symptoms such as high fever, rash, or neurological changes (e.g., confusion, seizures) occur, especially in infants or immunocompromised individuals. Prompt evaluation is recommended for severe or persistent symptoms.

Tips for Medical Coders

When coding for human herpesvirus 6 infection (B10.81), ensure documentation supports the diagnosis, including clinical presentation and any relevant laboratory findings. Differentiate between primary infection and reactivation when possible, as this may impact coding specificity. Verify that the code aligns with the patient’s documented condition and avoid using this code for infections caused by other herpesviruses.